• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination

tetano

Editor, Senior Moderator
Cell Rep


. 2022 Jan 31;110393.
doi: 10.1016/j.celrep.2022.110393. Online ahead of print.
B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination


Prasanti Kotagiri[SUP] 1 [/SUP], Federica Mescia[SUP] 2 [/SUP], William M Rae[SUP] 2 [/SUP], Laura Bergamaschi[SUP] 2 [/SUP], Zewen K Tuong[SUP] 3 [/SUP], Lorinda Turner[SUP] 2 [/SUP], Kelvin Hunter[SUP] 2 [/SUP], Pehuén P Gerber[SUP] 2 [/SUP], Myra Hosmillo[SUP] 4 [/SUP], Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration; Christoph Hess[SUP] 5 [/SUP], Menna R Clatworthy[SUP] 6 [/SUP], Ian G Goodfellow[SUP] 4 [/SUP], Nicholas J Matheson[SUP] 7 [/SUP], Eoin F McKinney[SUP] 2 [/SUP], Mark R Wills[SUP] 2 [/SUP], Ravindra K Gupta[SUP] 2 [/SUP], John R Bradley[SUP] 8 [/SUP], Rachael J M Bashford-Rogers[SUP] 9 [/SUP], Paul A Lyons[SUP] 10 [/SUP], Kenneth G C Smith[SUP] 11 [/SUP]



Affiliations

Abstract

B cells are important in immunity to both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and vaccination, but B cell receptor (BCR) repertoire development in these contexts has not been compared. We analyze serial samples from 171 SARS-CoV-2-infected individuals and 63 vaccine recipients and find the global BCR repertoire differs between them. Following infection, immunoglobulin (Ig)G1/3 and IgA1 BCRs increase, somatic hypermutation (SHM) decreases, and, in severe disease, IgM and IgA clones are expanded. In contrast, after vaccination, the proportion of IgD/M BCRs increase, SHM is unchanged, and expansion of IgG clones is prominent. VH1-24, which targets the N-terminal domain (NTD) and contributes to neutralization, is expanded post infection except in the most severe disease. Infection generates a broad distribution of SARS-CoV-2-specific clones predicted to target the spike protein, while a more focused response after vaccination mainly targets the spike's receptor-binding domain. Thus, the nature of SARS-CoV-2 exposure differentially affects BCR repertoire development, potentially informing vaccine strategies.

Keywords: B cell receptor repertoire; COVID-19; SARS-CoV-2 vaccination.
 
Back
Top Bottom